Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Addex Therapeutics (ADXN) Change in Receivables: 2022-2024

Historic Change in Receivables for Addex Therapeutics (ADXN) over the last 3 years, with Dec 2024 value amounting to $423.9 billion.

  • Addex Therapeutics' Change in Receivables rose 261.67% to $423.9 billion in Q4 2024 from the same period last year, while for Dec 2024 it was -$4.7 billion, marking a year-over-year decrease of 123.88%. This contributed to the annual value of $105,835 for FY2024, which is 68.99% down from last year.
  • As of Q4 2024, Addex Therapeutics' Change in Receivables stood at $423.9 billion, which was up 198.90% from -$428.7 billion recorded in Q3 2024.
  • Addex Therapeutics' Change in Receivables' 5-year high stood at $423.9 billion during Q4 2024, with a 5-year trough of -$428.7 billion in Q3 2024.
  • Moreover, its 3-year median value for Change in Receivables was $19,156 (2024), whereas its average is -$568.0 million.
  • Within the past 5 years, the most significant YoY rise in Addex Therapeutics' Change in Receivables was 492,631,284.59% (2023), while the steepest drop was 211,928,304.08% (2023).
  • Addex Therapeutics' Change in Receivables (Quarterly) stood at -$123,736 in 2022, then crashed by 211,928,304.08% to -$262.2 billion in 2023, then skyrocketed by 261.67% to $423.9 billion in 2024.
  • Its last three reported values are $423.9 billion in Q4 2024, -$428.7 billion for Q3 2024, and -$530,681 during Q2 2024.